Description: HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Home Page: www.hlstherapeutics.com
10 Carlson Court
Etobicoke,
ON
M9W 6L2
Canada
Phone:
647 495 9000
Officers
| Name | Title |
|---|---|
| Mr. Craig Stuart Millian M.B.A. | CEO & Director |
| Mr. John Hanna CPA, CGA, M.B.A. | CFO & Non-Independent Director |
| Dr. Jason A. Gross Pharm.D. | Vice President of Scientific Affairs |
| Mr. Ryan C. Lennox B.A., J.D. | Senior VP of Legal, HR & Compliance and Corporate Secretary |
| Mr. Brian T. Walsh | Chief Commercial Officer |
| Dave Mason | Investor Relations Officer |
| Mr. David Spence | VP & Corporate Controller |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9503 |
| Price-to-Sales TTM: | 1.287 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 91 |